Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002237 · ClinicalTrials.gov registry record · Phase 1

A Study of Peldesine (BCX-34) in HIV-Infected Patients

A Phase 1 study of HIV Infections, sponsored by BioCryst Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00002237 is a Phase 1 study of HIV Infections that has completed, run by BioCryst Pharmaceuticals. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002237, a Phase 1 study of HIV Infections, has completed, sponsored by BioCryst Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.

Conditions Studied

HIV Infections

Interventions

  • DRUG Peldesine

Study Locations (1)

California

  • Saint Francis Mem Hosp / HIV Care Unit - San Francisco

Trial Details

FieldValue
Phase Phase 1

Sponsor

BioCryst Pharmaceuticals

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002237

The ClinicalTrials.gov registry entry for NCT00002237 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Peldesine is the first listed.

NCT00002237 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00002237 about?

NCT00002237 is a clinical study titled "A Study of Peldesine (BCX-34) in HIV-Infected Patients". The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.

What is the current status of trial NCT00002237?

This trial is currently completed. It is a Phase 1 study.

What conditions does trial NCT00002237 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002237?

The interventions under investigation include: Peldesine (DRUG).

Who is sponsoring clinical trial NCT00002237?

This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002237 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.